Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21828612 | 1.00 | ACE (0.36) | ACEMMECPA1ACE2CTSC | |
| SCHEMBL31064827 | 0.95 | BACE1 (0.35) | ACE | |
| SCHEMBL29384990 | 0.93 | ACE (0.38) | ACEMME | |
| SCHEMBL79320 | 0.92 | ACE (0.36) | ACEMMECPA1ACE2CTSC | |
| SCHEMBL78173 | 0.92 | ACE (0.36) | ACEMMECPA1ACE2CTSC | |
| SCHEMBL78174 | 0.92 | ACE (0.36) | ACEMMECPA1ACE2CTSC | |
| SCHEMBL29532207 | 0.91 | MME (0.41) | MME | |
| SCHEMBL29849128 | 0.90 | MME (0.36) | ACEMME | |
| SCHEMBL29961809 | 0.90 | MME (0.45) | ACEMMECPA1ACE2 | |
| SCHEMBL29517172 | 0.90 | ERAP2 (0.35) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737477-A2 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | Protagonist Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | claimed |
| EP-4536683-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | Protagonist Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | claimed |
| US-20240293511-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | PROTAGONIST THERAPEUTICS, INC. | 2024-09-05 | — | — | US | claimed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | claimed |
| EP-4355763-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | Protagonist Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4314014-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117480176-A | Hepcidin mimetics for the treatment of hereditary hemochromatosis | 领导医疗有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | claimed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | claimed |
| CN-116457000-A | Conjugated hepcidin mimetics | 普罗塔格尼斯特治疗股份有限公司 | 2023-07-18 | — | — | CN | claimed |
| EP-4188412-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022266060-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2022-11-24 | — | — | US | claimed |
| WO-2022212698-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022212700-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-4025592-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| CN-114729022-A | Conjugated hepcidin mimetics | 领导医疗有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022026631-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | ACE 3636/4885MME 612/4885CPA1 348/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | ACE 3636/4885MME 612/4885CPA1 348/4885 |
| US-20240293511-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | HAMP, SLC40A1, FTH1 | ACE 3776/4885MME 496/4885CPA1 959/4885 |
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | ACE 2978/4885MME 345/4885CPA1 584/4885 |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, HDGF, FTH1 | ACE 4511/4885MME 2195/4885CPA1 874/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | ACE 4405/4885MME 809/4885CPA1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.